| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 196.47M | 283.42M | 494.71M | 645.94M | 661.89M | 823.54M |
| Gross Profit | 64.00M | 90.95M | 151.65M | 226.69M | 228.21M | 261.41M |
| EBITDA | -2.67M | 68.07M | 43.12M | 151.73M | 59.55M | 43.00M |
| Net Income | -12.77M | 52.59M | 22.22M | 129.98M | 48.78M | 14.31M |
Balance Sheet | ||||||
| Total Assets | 647.08M | 632.95M | 690.66M | 701.19M | 715.63M | 635.24M |
| Cash, Cash Equivalents and Short-Term Investments | 14.61M | 17.25M | 29.80M | 31.73M | 81.84M | 72.27M |
| Total Debt | 124.67M | 82.81M | 36.60M | 17.00M | 4.17M | 4.65M |
| Total Liabilities | 188.78M | 146.54M | 168.84M | 182.89M | 199.44M | 152.34M |
| Stockholders Equity | 392.37M | 419.24M | 455.51M | 453.36M | 450.94M | 418.25M |
Cash Flow | ||||||
| Free Cash Flow | -43.50M | -31.13M | -25.96M | -40.72M | 14.27M | 14.20M |
| Operating Cash Flow | -8.31M | 2.77M | 9.52M | -5.93M | 48.98M | 60.26M |
| Investing Cash Flow | -65.27M | -53.54M | -16.41M | -41.81M | -32.35M | -63.23M |
| Financing Cash Flow | 69.59M | 37.44M | 6.89M | -632.00K | -8.21M | -76.13M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | CHF325.20M | 10.49 | 14.20% | 2.52% | -1.94% | 6.63% | |
72 Outperform | CHF287.90M | 34.11 | ― | 0.16% | -0.64% | -5.79% | |
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
58 Neutral | $367.97M | 62.37 | 0.83% | 5.78% | -5.85% | -83.70% | |
50 Neutral | CHF336.97M | -3.28 | ― | 87.74% | ― | ― | |
48 Neutral | $334.41M | -26.29 | -3.04% | 2.70% | -56.09% | -118.83% | |
45 Neutral | $139.98M | -3.01 | -9.74% | ― | -15.70% | -670.93% |
Metall Zug AG reported a challenging first half of 2025, with net sales significantly declining to CHF 94.2 million, primarily due to the divestment of Belimed and negative currency effects. Despite these challenges, the company is optimistic about future growth, driven by new product launches from its Haag-Streit unit, including the world-first Elara 900 slit lamp. The ongoing integration of SteelcoBelimed is on track, with initial synergies expected to improve operational efficiency. The company is also undergoing a leadership change at Haag-Streit, with Thomas Lenzen taking over as CEO to continue driving international growth and innovation.
The most recent analyst rating on (CH:METN) stock is a Hold with a CHF1082.00 price target. To see the full list of analyst forecasts on Metall Zug AG stock, see the CH:METN Stock Forecast page.